Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on March 1, 2024, covering events occurring on February 28, 2024. The Company is a biopharmaceutical firm focused on structure-based drug discovery, with its principal executive offices in Bothell, WA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material corporate event rather than periodic financial results.
Material Changes
- Termination of Agreements: On February 28, 2024, the Company notified Kansas State University Research Foundation of its election to terminate License Agreements dated February 12, 2020, and April 19, 2020.
- Effective Date: The terminations are effective March 29, 2024.
- Rationale: Management determined that further development efforts under these specific agreements would be futile.
Outlook, Management Commentary, and Risks
Management clarified that the Company's proprietary compound, CDI-988, a pan-viral therapeutic for coronavirus and norovirus, is wholly owned and not affected by these terminations. CDI-988 is currently progressing in a Phase 1 clinical trial. The primary risk highlighted is the cessation of development under the terminated university licenses, though the Company maintains its core proprietary pipeline.
Key Facts for Investor Verification
- Confirm the specific financial impact of terminating the Kansas State University Research Foundation agreements.
- Verify the current status and timeline of the Phase 1 clinical trial for CDI-988.
- Review the Company's cash runway given the lack of revenue and the strategic shift away from the terminated licenses.
- Check for any potential legal or financial obligations remaining from the terminated agreements post-March 29, 2024.